MRVI Maravai LifeSciences
- 8.420
- +0.220+2.68%
- 8.230
- -0.190-2.26%
Maravai LifeSciences News
Craig-Hallum Keeps Their Buy Rating on Maravai Lifesciences Holdings (MRVI)
Analysts Offer Insights on Healthcare Companies: Diamedica Therapeutics (DMAC), Inspire Medical Systems (INSP) and Maravai Lifesciences Holdings (MRVI)
Maravai LifeSciences Analyst Ratings
Craig-Hallum Initiates Coverage On Maravai LifeSciences With Buy Rating, Announces Price Target of $15
RBC Capital Sticks to Its Buy Rating for Maravai Lifesciences Holdings (MRVI)
RBC Raises Price Target on Maravai LifeSciences Holdings to $15 From $14, Keeps Outperform Rating
Analysts Offer Insights on Healthcare Companies: Maravai Lifesciences Holdings (MRVI) and R1 RCM (RCM)
Buy Rating Affirmed for Maravai Lifesciences Amid Strong Financial Performance and Growth Outlook
UBS Adjusts Maravai LifeSciences Price Target to $6.50 From $6, Maintains Neutral Rating
Maravai LifeSciences Analyst Ratings
RBC Raises Price Target on Maravai LifeSciences Holdings to $14 From $12, Cites 'Clean' Q4, Keeps Outperform Rating
Stifel Nicolaus Sticks to Its Buy Rating for Maravai Lifesciences Holdings (MRVI)
Maravai Lifesciences Holdings: Poised for Growth With Strong Q4 Performance and Promising FY2024 Outlook
RBC Capital Reaffirms Their Buy Rating on Maravai Lifesciences Holdings (MRVI)
Maravai LifeSciences Analyst Ratings
RBC Capital Sticks to Its Buy Rating for Maravai Lifesciences Holdings (MRVI)
Morgan Stanley Maintains Overweight on Maravai LifeSciences, Lowers Price Target to $11
Maravai LifeSciences Analyst Ratings
Deutsche Bank Adjusts Maravai LifeSciences Price Target to $10 From $17, Maintains Buy Rating
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK), Maravai Lifesciences Holdings (MRVI) and Karuna Therapeutics (KRTX)
Analysis
Price Target
No Data
